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segmental glomerulosclerosis (FSGS, 27%) and IgM nephropathy
(11%). Median age was 7.8 (Range 2.5 – 16.5) years with median
follow up post rituximab 33 (Range 1.5 to 87) months. Rituximab
was given as infusion at 375 mg / m2 . Each cycle constituted of
2 injections at an interval of 1-2 weeks followed by conﬁrmation of
B cell depletion. Single cycle achieved total B-cell depletion in all.
5 cases (all SRNS) received 2. Median duration for normalisation of
CD 19 was 4.65 (3 – 7) months. Among the SRNS, serum albumin
rose from mean 1.87 (SD  0.53) to 2.63 (SD  1.1) g/dl, (p¼0.06)
and UPCR fell from mean 19.3 (SD  12.04) to 9.8 (SD  10.96)
p¼ 0.15. 20% of SRNS (n¼2) achieved CR another 20% PR. Steroid
threshold among SDNS/FRNS fell from mean 0.47 (SD  0.19) to
0.17 (SD  0.23) mg/kg, p ¼0.0003 and dose of steroid at last follow
up fell men 0.88 (SD  0.56) to 0.22 (SD  0.43) mg/kg, p ¼0.0009.
50% of SDNS/FRNS (n¼11) did not have any relapse during the
follow up period and median time to ﬁrst relapse was 6.6 (Range 0.3
– 25) months.
Conclusions: Rituximab was demonstrated to be useful with sig-
niﬁcant beneﬁt particularly in the SDNS group.
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Introduction: Phospholipase A2 receptor 1 (PLA2R1) and throm-
bospondin type-1 domain-containing 7A (THSD7A) are podocyte
membrane proteins that have been identiﬁed as target antigens for
autoimmunity in membranous nephropathy (MN). The investiga-
tion of the pathogenicity of the involved autoantibodies has been
hampered by the fact that PLA2R1 is not expressed on rodent
podocytes. On the other hand, THSD7A is expressed on mouse
podocytes and shares over 90% of sequence homology with the
human protein. We have recently demonstrated that anti-THSD7A
antibodies isolated from a patient with THSD7A- associated MN can
cause morphological and clinical MN in mice, allowing further
investigations of disease pathogenesis. However, THSD7A-associ-
ated MN is a rare entity, incapacitating patient antibodies for larger
experimental procedures.
Methods: We generated polyclonal antibodies against human and
mouse THSD7A in rabbits using cDNA immunization. IgG from the
immunized rabbits and from preimmune control rabbits was af-
ﬁnity-puriﬁed and intravenously injected into mice. Urine was
collected daily and investigated for the development of proteinuria
by measurement of albumin-to-creatinine ratios. Mice were sacri-
ﬁced ﬁve, nine, and fourteen days after injection of rabbit IgG and
kidneys were analyzed using confocal and light microscopy.
Results: Puriﬁed IgG from immunized rabbits recognize, like pa-
tient autoantibodies, (a) conformation-dependent epitope(s) present
in both native human and mouse THSD7A in vitro. Moreover, two
hours after intravenous injection into mice, rabbit IgG is bound
along the glomerular ﬁltration barrier. Two days later, mice developS2proteinuria that rapidly increases and reaches around 10 g/g after
5 days and 200-300 g/g albumin-to-creatinine after 14 days with
some mice developing a severe nephrotic syndrome with ascites and
hyperlipidemia. In immunoﬂuorescent analysis, granular rabbit IgG
is found subepithelially along the glomerular ﬁltration barrier after
14 days and immunohistochemistry for rabbit IgG shows the classic
picture of human MN. Mice injected with puriﬁed IgG from rabbit
serum that was taken before THSD7A-immunization fail to develop
any of these changes.
Conclusions: Our study introduces a heterologous mouse model
that allows further mechanistic investigations of the molecular
events leading to membranous nephropathy.
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Introduction: The complement system can be activated via three
pathways, the classical (CP), alternative (AP) and lectin pathway
(LP). Studies have shown a role for complement in renal diseases
such as hemolytic uremic syndrome, C3 glomerulopathy and renal
transplantation. It is well known that heparin and some other
glycosaminoglycans (GAGs) inhibit complement activation. We
tested the pathway speciﬁc complement inhibiting potential of >70
GAGs. The results showed that some GAGs had a speciﬁc inhibitory
effect on the LP only. In this work we unravel the inhibitory
mechanism of GAGs on the LP.
Methods: GAGs were tested in the Wieslab complement screening
assay for a dose-dependent inhibition assay of the complement
pathways. Inhibition of ﬁcolin-3 mediated LP activation by GAGs
was tested in the Wieslab ﬁcolin-3 assay. To assess whether GAGs
inhibit the MBL – mannan interaction, GAGs were added to diluted
serum and incubated on mannan coated plates where after depo-
sition of MBL was measured. To test the inhibition of GAGs on
MASP activity, the GAGs were added to puriﬁed C4 and incubated
on MBL-MASP coated plates, C4 activation was measured by
detection of C4b. To assess whether the MBL-MASP complex binds
to heparin, serum was incubated on heparin-albumin coated plates
and binding of MBL, MASP-1 and MASP-2 was measured.
Results: In the Wieslab complement screening assay, (LMW-)hep-
arin dose-dependently inhibited all three pathways of complement.
Depolymerization of heparin followed by size-fractionation of the
resultant oligosaccharides revealed hexasaccharides and tetra-
saccharides to exclusively inhibit the LP, without any inhibition
potential for the CP and AP. Heparin (oligo’s) also show a dose-
dependent inhibition of the ﬁcolin-3 mediated LP activation,
however failed to inhibit the binding of MBL to mannan, indicating
inhibition by GAGs of MASP1/2 enzymes. This was proven in the
MASP-1/2 inhibition assays. Heparin (oligo’s) inhibited the C4
cleavage by MASP-1/2 in a dose-dependent way. Comparison of
deﬁned heparin-derived tetrasaccharides with various sulfation
revealed the fully N-, 2-O, 6-O-sulfated fragment the most potent
MASP-1/2 inhibitor. Vice versa the MBL-MASP complex showsKidney International Reports (2016) 1, S1–S22
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likely via MASP-1/2 – heparin interaction.
Conclusions: Our data identiﬁes small heparin-derived oligosac-
charide inhibitors speciﬁc for the LP. We show that the LP
inhibitory effect of GAGs is via blocking the enzymatic activity of
the MASP enzymes. Binding of the MBL-MASP complex to
immobilized heparin indicates that heparan sulfate/heparin struc-
tures on cells and in extracellular matrix in vivo might act as
docking platforms for the MBL-MASP complex. These results
might be important for renal diseases with LP involvement.
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Introduction: B cell depletion, most commonly with rituximab
(RTX), has emerged as a potential therapeutic strategy in SLE,
particularly in patients who are unresponsive to, or intolerant of,
standard therapy. Ofatumumab is a fully humanised anti-CD20
monoclonal antibody directed against distinct extra-cellular epitope
on CD20, which has shown efﬁcacy in the treatment of haemato-
logical malignancy. Since 2012, we have been using ofatumumab on
compassionate grounds in patients with SLE for whom B cell
depletion is deemed a desirable therapeutic approach, but who are
allergic to RTX.
Methods: This is a retrospective report of SLE cases treated with
ofatumumab at our centre between 2012-2015. Data are reported as
medians +/- IQR, and comparisons are by non-parametric testing,
unless otherwise stated.
Results: In total, 15 patients received ofatumumab: all female, mean
age 33 years, median duration of SLE 7.5 years (range 1-18). 46%
had previously been treated with cyclophosphamide and all had
previously received RTX (median time since last treatment 4.5
months). All had severe infusion reactions to RTX previously. Two
patients demonstrated infusions reactions to ofatumumab, such that
they did not receive full dosing and have therefore been excluded
from subsequent analysis.
Of the remaining 13 cases, ten were treated for disease ﬂares
complicated by lupus nephritis (LN); three patients were treated for
extra-renal disease. Our standard treatment protocol is ofatumumab
2x700mg iv doses, with MMF maintenance and minimal steroids.
Following treatment, two patients did not achieve B cell depletion
(BCC<20). In those who did deplete, the median time to depletion
was 16 days, and to subsequent reconstitution (BCC>20) 4.8
months (see Figure). Treatment was associated with signiﬁcant
improvements in serological markers of disease activity at 6 months
(see Figure & Table).Kidney International Reports (2016) 1, S1–S22At 0 months At 6 months p valueANA, titre (median+/-IQR) 2560 (240-2560) 320 (200-2080) 0.012dsDNA, iu (median+/-IQR) 331 (234-717) 132 (73-429) 0.001C3, g/L (median+/-IQR) 0.69 (0.52-0.99) 0.83 (0.65-1.10) 0.022C4, g/L (median+/-IQR) 0.12 (0.08-0.18) 0.14 (0.07-0.25) nsThree patients with LN did not respond to treatment (>1.5x
rise in serum creatinine at 6 months). The remaining patients
had stable renal function (<10% increase or improved serum
creatinine) with improved proteinuria (median uPCR 424 to
99 mg/mmol) at 6 months. At last followup (median duration
32months), no opportunistic infections, malignancies, new episodes
of hypogammaglobulinaemia, or deaths have been observed. Three
patients had further severe disease ﬂares requiring hospitalisation
and escalation of treatment.
Conclusions: In this heavily pre-treated cohort, with longstanding
SLE refractory to conventional treatment, ofatumumab was effec-
tive for B cell depletion in patients who were intolerant of ritux-
imab. Treatment was associated with serological and clinical
response, although a proportion of patients had progressive disease.
No unexpected safety signals were seen. Larger controlled studies
are desirable to further deﬁne the role of ofatumumab in the
treatment of SLE. Pending these studies, ofatumumab may be
considered for patients who are intolerant of RTX, and for whom B
cell depletion is still a desirable treatment strategy.
P07
SHOULD PATIENTS UNDERGOING
RENAL TRANSPLANT WITHOUT
INDUCTION WITH BIOLOGIC AGENTS,
RECEIVE CYTOMEGALOVIRUS
CHEMOPROPHYLAXIS?
Rangaswamy, D1, Kaza, S2, Nagaraju, S2, Attur, R2
1Kasturba Medical College- Manipal University, Nephrology, Manipal, India;
2Kasturba Medical College, Nephrology, Manipal, India
Introduction: Cytomegalovirus (CMV) is a frequently encountered
opportunistic pathogen in renal transplant recipients (RTR). Spec-
trum of CMV infection ranges from latent infection to life-threat-
ening multisystem disease. Current KDIGO guidelines recommend
RTR to receive a biologic induction agent and all RTR (except in D-/
R- CMV serology) to receive chemoprophylaxis for CMV infection
with oral ganciclovir or valganciclovir for at least 3 months post
transplantation. Currently no guidelines exist for use of CMV
prophylaxis in patients transplanted without a biologic induction.S3
